RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $49.02, for a total transaction of $151,962.00. Following the completion of the transaction, the insider now owns 42,246 shares of the company’s stock, valued at approximately $2,070,898.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total transaction of $353,250.00.

RxSight Price Performance

NASDAQ RXST opened at $47.15 on Wednesday. RxSight, Inc. has a 1 year low of $20.66 and a 1 year high of $66.54. The company has a market capitalization of $1.74 billion, a PE ratio of -37.42 and a beta of 1.22. The company has a fifty day moving average of $51.16 and a two-hundred day moving average of $53.90.

RxSight (NASDAQ:RXST) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The company had revenue of $34.89 million during the quarter, compared to the consensus estimate of $32.33 million. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. RxSight’s revenue for the quarter was up 67.6% on a year-over-year basis. On average, research analysts expect that RxSight, Inc. will post -0.81 earnings per share for the current year.

Hedge Funds Weigh In On RxSight

Large investors have recently bought and sold shares of the stock. RA Capital Management L.P. boosted its stake in shares of RxSight by 1.1% during the first quarter. RA Capital Management L.P. now owns 3,442,825 shares of the company’s stock worth $177,581,000 after buying an additional 38,540 shares during the period. Vanguard Group Inc. boosted its stake in shares of RxSight by 2.7% during the first quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock worth $78,634,000 after buying an additional 40,500 shares during the period. Driehaus Capital Management LLC boosted its stake in shares of RxSight by 74.9% during the second quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock worth $42,490,000 after buying an additional 302,367 shares during the period. Parkman Healthcare Partners LLC boosted its stake in shares of RxSight by 34.5% during the fourth quarter. Parkman Healthcare Partners LLC now owns 513,032 shares of the company’s stock worth $20,685,000 after buying an additional 131,701 shares during the period. Finally, Baillie Gifford & Co. boosted its stake in shares of RxSight by 438.8% during the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock worth $21,554,000 after buying an additional 291,733 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on RXST. Needham & Company LLC restated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Oppenheimer decreased their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Wells Fargo & Company lowered their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. BTIG Research upped their price objective on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, Stifel Nicolaus lowered their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, RxSight presently has a consensus rating of “Buy” and an average price target of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.